Other genetic tests

The scope of genetic testing is based on the results of the genetic consultation. If there is already a family history of a disease with a genetic component, the examination is targeted to a specific area.

None

We perform the targeted laboratory test either in our laboratory or send the sample to another laboratory, including specialized laboratories abroad, as part of interlaboratory cooperation. Another group of tests investigates hidden predispositions to genetic diseases that everyone is likely to pass on to their offspring.

Chromosomal examination (karyotype)

What are chromosomes?

Chromosomes are blocks of genes of a typical shape and number stored in the nuclei of all cells. Humans have 23 pairs of chromosomes, for a total of 46 chromosomes. One member of the pair comes from the mother, the other from the father. Mature sex cells - eggs and sperm - have half the number of chromosomes because the pairing occurs at conception.

According to the size and characteristic bands, the chromosomes can be grouped into a set - a karyotype. A female has two X sex chromosomes, a male has one X sex chromosome and one Y sex chromosome. The normal female karyotype is written 46.XX, the normal male karyotype 46.XY.

Chromosomal defects (aberrations) Chromosomal aberrations are variations in the number or shape of chromosomes and usually put the carrier or his or her offspring at risk of severe changes in genetic makeup affecting a number of organs. Currently, there is neither effective prevention nor targeted treatment for chromosomal aberrations and the life prognosis of those affected is often unfavourable.

Chromosome number disorders (aneuploidy)

Trisomy occurs when a "trio" rather than a chromosomal pair is formed at conception; it means that the affected individual has 47 rather than 46 chromosomes in each cell of each organ; it usually occurs randomly during egg or sperm maturation; the risk of trisomy increases with maternal age; trisomy most often affects chromosome number: 21 - Down's syndrome, 18 - Edwards syndrome, 13 - Patau syndrome, as well as the X and Y sex chromosomes.

Chromosome shape disorders affect only parts of the chromosomes. There may be a loss (deletion) of genetic information or an excess (duplication) of genetic information.

Chromosomal aberrations may be inherited from the mother (maternal), from the father (paternal), or may be newly created (de novo). Aneuploidy usually occurs randomly and its risk increases with maternal age. While some aneuploid embryos may develop until the baby is born (e.g. Down syndrome), most pregnancies of aneuploid embryos end in spontaneous abortion.

Some chromosomal aberrations do not always imply a change in the genetic make-up of the cell - the aberration is balanced and the carrier is usually healthy. However, there is a risk that the carrier will have an unbalanced part of his/her sex cells (female egg, male sperm) and this may then manifest itself in estrus or recurrent miscarriage. For this reason, karyotyping of both partners is an essential preconception genetic test.
What are the precautions when chromosomal aberrations are found in the parents-to-be?

When there is a significant risk of chromosomal defect for the future child and/or risk of pregnancy failure, we recommend assisted conception (IVF) and selection of chromosomally balanced embryos suitable for transfer to the uterus (preimplantation diagnosis).

Thrombophilic mutations

Thrombophilia

Thrombophilia is a tendency to increased blood clotting, which is influenced by both innate dispositions and external influences (e.g. exercise, weight, age, smoking, injury, medication). People with a higher blood clotting capacity are at greater risk of blood clots (thrombi), which can lead to partial or complete closure of blood vessels - most commonly the deep veins of the lower limbs (deep vein thrombosis). A part of the clot may break loose, travel through the venous system and close a pulmonary vessel after passing through the heart - resulting in a pulmonary embolism. Thrombosis of the placenta can threaten the course of pregnancy.

The external stimulus for the formation of blood clots may be hormonal contraception, hormonal treatment of infertility or the period of pregnancy, therefore the examination of the inherited component of thrombophilia belongs to the basic preconception genetic examination. The results of the testing influence the treatment of fertility disorders and the care of pregnant women. Knowledge of the innate disposition to blood clotting can help not only in the reproductive period of life, but also during surgery, long-term immobilization or
treatment of chronic diseases.

We are investigating two important alterations - thrombophilic mutations in the F5 and F2 genes, which affect the composition and function of two proteins (factor V and factor II) that are significantly involved in the blood clotting process:
- Leiden mutation (FV Leiden) of the gene for clotting factor V - a mutation at position 1691 in the F5 gene leads to a substitution of the amino acid arginine for glutamine at position 506 (R506Q) of this protein.
- Mutation of the gene for clotting factor II (F II prothrombin) - mutation at position 20210 of the F2 gene. The finding of the mutation indicates an increased innate disposition to blood clotting, and certain preventive measures must be implemented. In the Czech population, 5-10% of carriers of the FV Leiden mutation and 1-2% of carriers of the FII prothrombin mutation.

How is thrombophilia inherited?

Thrombophilic mutations are transmitted from generation to generation. We recognize:

- heterozygotes: an individual who has inherited the mutation from only one parent; his or her liver produces a mixture of normal and altered clotting factor and has an increased risk of developing thrombosis,
- homozygotes: an individual who has inherited the same mutation from both parents; his/her liver produces only the more active clotting factor with a more pronounced effect and therefore has a very high risk of developing thrombosis.

It is an autosomal dominant inheritance; a heterozygote (carrier of one mutation) has a 50% risk of passing the mutation to his/her children regardless of their sex; a homozygote will always pass the mutation to his/her children.

What is the risk of developing thrombosis?

The presence of an inherited thrombophilic mutation poses a 3-5 times higher risk of developing deep vein thrombosis compared to the general population, but this does not mean that every carrier will suffer from thrombosis. The development of thrombosis usually occurs only through the co-action of other acquired thrombophilic factors:
- age over 45 years,
- obesity, smoking, alcohol,
- atherosclerosis and other cardiovascular diseases,
- abdominal and orthopaedic surgery,
- trauma and long-term immobilisation,
- use of hormonal contraceptives or treatment with sex hormones (thrombophilic mutations are contraindicated in homozygotes),
- pregnancy and six months of childbirth,
- oncological diseases and their treatment,
- loss or insufficient fluid intake (dehydration),
- autoimmune diseases (e.g. antibodies to phospholipids),
- the presence of mutations in other genes associated with blood clotting.

If multiple thrombophilic factors come together, thrombosis can occur in anyone, but in individuals with congenital thrombophilia, minor external influences are sufficient to induce thrombosis.

What is the prevention against the development of thrombosis?

Knowledge of genetic predispositions is a key element in preventing and minimizing problems associated with thrombosis. This information can be used to tailor a lifestyle - getting enough exercise, taking in adequate fluids, following a rational diet, maintaining an optimal body weight, not smoking. These basic measures can significantly reduce the risk of disease.

At the same time, haematological monitoring or therapy is provided in situations of risk - for example, during pregnancy. If medical interventions are necessary, the attending physician should always be informed of the tendency to increased blood clotting!

Cystic fibrosis

Cystic fibrosis

Cystic fibrosis is a serious and incurable inherited disease caused by mutations in the CFTR gene, which controls the activity of the chloride channel in the cell membrane. The disease affects many organs, especially the respiratory, digestive and reproductive systems. A thick mucus builds up in the patient's lungs and harbours bacteria, leading to repeated respiratory infections and permanent damage to the lungs. Patients also often have nutritional problems, as the pancreas does not properly produce digestive enzymes, and so they do not thrive and gain weight despite a high-calorie diet. Men are infertile, having no sperm present (azoospermia) due to the congenital absence of the vas deferens.

How is cystic fibrosis inherited?

CF is an autosomal recessively inherited disease, which means that the presence of two mutations in a patient is necessary for the development of the disease - one mutation inherited from the mother, the other from the father. Therefore, the parents of the patient are healthy carriers of the mutation (disease susceptibility) and have a 25% chance of having a child with cystic fibrosis. In the Czech population, every 26th person carries a CFTR gene mutation!

What is genetic testing for CF?

The aim of genetic testing is to confirm or exclude mutations in the CFTR gene in the patient under examination. To date, there are about 1800 known mutations, the most common of which is the F508del mutation. Our test detects 50 CFTR gene mutations commonly found in the European population; their absence reduces the risk of carrying a CFTR gene mutation to 1 in 400. In the case of a proven mutation, molecular genetic testing of the wider family is recommended for the prevention of CF.

What is the prevention of cystic fibrosis?

Cystic fibrosis is currently an incurable disease whose consequences can only be mitigated by early diagnosis. The only prevention against the birth of a child affected by CF is the use of assisted reproductive techniques with preimplantation diagnosis (PGD), where only genetically healthy embryos are selected for transfer into the uterus. If a woman becomes pregnant naturally, she can undergo prenatal diagnosis (genetic testing of the fetus in pregnancy) and if the fetus is found to be affected, the pregnancy can be terminated for genetic reasons.

Paternity test

Paternity test

Proof (or demonstration) of paternity is done by testing blood or other biological samples. Methods used in forensic science compare the genetic features stored in the DNA of the mother, the putative father and the offspring.

Paternity
- is proven with a probability of more than 99.9%
- is ruled out with 100% certainty.

At the REPROFIT clinic we offer the following paternity testing

Paternity test by agreement between the mother and the putative father:
- results cannot be used for legal acts!

Non-invasive paternity test by agreement from the 11th week of pregnancy:
- only the blood of the mother and the presumed father is examined,
- the test can only be performed in singleton pregnancies.

Other treatment options

None

IVF with your own eggs

Infertility afflicts a large number of couples. We know how to help.

None

IVF with donated eggs

We have specialized in treatment with donated eggs since the clinic was founded. Thanks to our extensive database of donors, we can choose the most suitable one for you.

None

IVF with donated embryos

Thanks to our sophisticated egg donation program, we have the unique opportunity to offer infertile couples treatment with donated embryos.

None

The first step to parenting from the comfort of home

Our doctors are also here for you online. We provide free consultations, we will make an appointment without waiting and without the need to present a request form.

Contact form

Contact formular

Please fill out
Please fill out
Please fill out
Max 500 characters

Our clinics

None

Reprofit Brno

en fr cs sk de it ro pl hu
More information
None

Reprofit Ostrava

en cs pl
More information
None

Reprofit Bratislava

en sk hu
More information
None

Reprofit Martin

en sk
More information